Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
You could win a cash prize of up to £25,000 when you play the Breakthrough T1D lottery. As well as the chance to win great prizes, you’ll also help fund our research to find a cure for type 1 diabetes.
Invite your friends, family, colleagues or clients to an exceptional black-tie event in the heart of London. Every ticket, every bid, every moment helps us move closer to a cure.
Our ambitious new roadmap is aimed at driving significant advancements in type 1 diabetes research, treatment, and care.
Join the type 1 diabetes community and come together, raising awareness and vital funds for T1D.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
JDRF has now rebranded to Breakthrough T1D. Our name has changed, our mission has not.
Home > News & events > News > Promising stem cell therapy for type 1 given green light to progress
A picture of beta cells made in a lab from stem cells, which can be grown into any cell.
VX-880 is an exciting potential treatment for type 1 diabetes involving transplanting lab grown insulin-producing beta cells into people with T1D. This allows the body to produce its own insulin again, reducing the need for insulin injections.
A clinical trial is currently underway in the United States to test the therapy in participants with type 1. Read more about what clinical trials are.
All the participants recruited for the trial of VX-880 have impaired hypoglycemic awareness, meaning they struggle to tell when they are having a hypo, which results in severe hypoglycemia.
So far, two people have been given half the maximum planned dose of new beta cells. They have all shown a significant improvement in their diabetes management, measured by more time in range and less insulin needed.
One participant has even become insulin-independent, meaning they can now produce all their required insulin themselves and no longer need to inject.
This improvement with just half the intended dose led the FDA – the organisation that licenses treatments in the US – to put the trial on hold because they did not see enough evidence for increasing the dose.
The FDA has just lifted this hold on VX-880, allowing the clinical trial to continue. This means the study can recruit more participants to receive the beta cell transplant, this time at the full dose.
The safety and effectiveness of the full dose of VX-880 will first be assessed in five new participants before being extended to a handful more people.
The beta cells used in VX-880 are made in a lab by scientists from stem cells. Making the cells in this way means no donors are needed to donate their healthy beta cells. The lack of available donors has previously limited the number of people with type 1 who could benefit from transplants, which will no longer be an issue if the trial of VX-880 is successful.
Watch this video to hear from scientists who are growing beta cells in their lab.
Since 2000, we have been funding a scientist called Doug Melton to make beta cells from stem cells. He succeeded and we invested more money in his company Semma to turn these cells into a cure for type 1. Another company called Vertex took over Semma, and Doug is now working at Vertex to bring his original research closer to a functional cure for type 1.
It’s thanks to our incredible supporters that we were able to fund this initial research. Find out how you can support us.
New data from Sana Biotechnology, in collaboration with Uppsala University Hospital in Sweden, shows that six months post-transplant, one person with type 1 diabetes (T1D) is successfully producing insulin and does not require immunosuppression.
US-based company Vertex has published promising figures from their cell therapy trial, showing advancements in stem cell research.
Breakthrough T1D has helped organise an event hosted by Tomislav Sokol titled ‘Accelerating Breakthroughs to Address Unmet Needs in Type 1 Diabetes.’
The award recognises Professor Dayan’s remarkable accomplishments in type 1 diabetes research.
Our research is improving the lives of people with type 1 and making strides towards a cure. We’ll keep pushing until we make type 1 diabetes a thing of the past.
